The FDA approved ivosidenib for patients with IDH1-mutant relapsed/refractory 
acute myeloid leukemia. The approval was based on results of a phase I trial in 
which 32.8% of patients treated with the drug had a complete remission or a 
complete remission with a partial hematologic recovery.